

Daniel Fuster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7785239/publications.pdf>

Version: 2024-02-01

75
papers

1,166
citations

361296

20
h-index

434063

31
g-index

77
all docs

77
docs citations

77
times ranked

1618
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Natural Killer Cells Are Associated with Alcohol Liver Fibrosis and with T Cell and Cytotoxic Subpopulations Change. <i>Journal of Clinical Medicine</i> , 2022, 11, 305.	1.0	7
2	Abuse Potential of Cathinones in Humans: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1004.	1.0	13
3	Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004–2018. <i>BMC Infectious Diseases</i> , 2022, 22, 379.	1.3	5
4	Utilizaci3n de opioides para el dolor cr3nico no oncol3gico. Respuesta. <i>Medicina Cl3nica</i> , 2021, 156, 98-99.	0.3	0
5	Long-Term Outcomes of Patients With Cocaine Use Disorder: A 18-years Addiction Cohort Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 625610.	1.6	7
6	Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients. <i>Viruses</i> , 2021, 13, 716.	1.5	0
7	Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use. <i>World Journal of Gastroenterology</i> , 2021, 27, 3223-3237.	1.4	2
8	Markers of Monocyte Activation, Inflammation, and Microbial Translocation Are Associated with Liver Fibrosis in Alcohol Use Disorder. <i>Journal of Clinical Medicine</i> , 2021, 10, 3496.	1.0	2
9	Lack of Association Between Recent Cannabis Use and Advanced Liver Fibrosis Among HIV-positive Heavy Drinkers. <i>Current HIV Research</i> , 2021, 19, 324-331.	0.2	2
10	Use of opioids for chronic non-cancer pain. Reply. <i>Medicina Cl3nica (English Edition)</i> , 2021, 156, 98-99.	0.1	0
11	Sex-specific Associations of Alcohol Withdrawal in Patients Admitted for the Treatment of Alcohol Use Disorder. <i>Journal of Addiction Medicine</i> , 2021, 15, 68-73.	1.4	8
12	Correlates of the use of electronic devices to vape cannabis in a cohort of young Swiss male reporting current cannabis use. <i>European Journal of Public Health</i> , 2021, 31, 437-441.	0.1	2
13	Significance of Markers of Monocyte Activation (CD163 and sCD14) and Inflammation (IL6) in Patients Admitted for Alcohol Use Disorder Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 152-158.	1.4	7
14	Liver fibrosis and accelerated immune dysfunction (immunosenescence) among HIV-infected Russians with heavy alcohol consumption - an observational cross-sectional study. <i>BMC Gastroenterology</i> , 2020, 20, 1.	0.8	26
15	Cannabis use is associated with monocyte activation (sCD163) in patients admitted for alcohol use disorder treatment. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108231.	1.6	1
16	Loss of naive T lymphocytes is associated with advanced liver fibrosis in alcohol use disorder. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108046.	1.6	12
17	Cocaine Use: A Threat for the HIV-Infected Liver. <i>Journal of Women's Health</i> , 2020, 29, 1141-1142.	1.5	0
18	Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral na3ve persons with alcohol use in Russia. <i>PLoS ONE</i> , 2019, 14, e0218852.	1.1	14

#	ARTICLE	IF	CITATIONS
19	Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. PLoS ONE, 2019, 14, e0221598.	1.1	7
20	Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles. Journal of Community Health, 2019, 44, 1044-1054.	1.9	18
21	Liver Ultrasound Abnormalities in Alcohol Use Disorder. , 2019, , .		0
22	Empiema necessitatis 17 años después de una neumonectomía. Medicina Clínica, 2018, 150, 493-494.	0.3	0
23	The opioid crisis. Medicina Clínica (English Edition), 2018, 151, 487-488.	0.1	1
24	Alcohol Use in Patients with Chronic Liver Disease. New England Journal of Medicine, 2018, 379, 2577-2579.	13.9	2
25	Alcohol Use in Patients with Chronic Liver Disease. New England Journal of Medicine, 2018, 379, 1251-1261.	13.9	137
26	Hepatitis C infection substantially reduces survival of alcohol-dependent patients. Clinical Epidemiology, 2018, Volume 10, 897-905.	1.5	7
27	Current Opioid Access, Use, and Problems in Central and Western European Jurisdictions. Current Addiction Reports, 2018, 5, 478-484.	1.6	2
28	La crisis de los opioides. Medicina Clínica, 2018, 151, 487-488.	0.3	10
29	Ultrasound findings of liver damage in a series of patients consecutively admitted for treatment of alcohol use disorder. Drug and Alcohol Dependence, 2018, 190, 195-199.	1.6	5
30	Cardiovascular disease burden among human immunodeficiency virus-infected individuals. International Journal of Cardiology, 2018, 265, 195-203.	0.8	23
31	HIV And HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1551-1556.	0.6	13
32	Long-Term Mortality of Patients with an Alcohol-Related Wernicke-Korsakoff Syndrome. Alcohol and Alcoholism, 2017, 52, 466-471.	0.9	27
33	Folate deficiency in patients seeking treatment of alcohol use disorder. Drug and Alcohol Dependence, 2017, 180, 417-422.	1.6	18
34	Cannabis as Secondary Drug Is Not Associated With a Greater Risk of Death in Patients With Opiate, Cocaine, or Alcohol Dependence. Journal of Addiction Medicine, 2017, 11, 34-39.	1.4	5
35	Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World Journal of Hepatology, 2016, 8, 1295.	0.8	37
36	Systematic review and meta-analysis of hepatitis C virus infection and HIV viral load: new insights into epidemiologic synergy. Journal of the International AIDS Society, 2016, 19, 20944.	1.2	4

#	ARTICLE	IF	CITATIONS
37	Wide array of T-cell subpopulation alterations in patients with alcohol use disorders. <i>Drug and Alcohol Dependence</i> , 2016, 162, 124-129.	1.6	9
38	Impact of Hepatitis C Virus Infection in the Liver-Related Mortality of Patients with Alcohol use Disorder. <i>Journal of Hepatology</i> , 2016, 64, S240-S241.	1.8	1
39	Brief Intervention for Daily Marijuana Users Identified by Screening in Primary Care: A Subgroup Analysis of the ASPIRE Randomized Clinical Trial. <i>Substance Abuse</i> , 2016, 37, 336-342.	1.1	14
40	Markers of Inflammation and Mortality in a Cohort of Patients With Alcohol Dependence. <i>Medicine (United States)</i> , 2015, 94, e607.	0.4	19
41	Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 18-24.	1.0	19
42	Hepatitis C asociada al abuso de sustancias: nunca tan cerca de un tratamiento sin Interferón. <i>Revista De Psicología De La Salud</i> , 2015, 27, 141.	0.2	2
43	Hepatitis C associated to substance abuse: ever closer to a treatment without Interferon. <i>Revista De Psicología De La Salud</i> , 2015, 27, 141-9.	0.2	1
44	Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. <i>Aids</i> , 2014, 28, 1059-1064.	1.0	25
45	Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study. <i>BMC Infectious Diseases</i> , 2014, 14, 504.	1.3	5
46	Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. <i>Addiction</i> , 2014, 109, 62-70.	1.7	24
47	Temporal trends in the survival of drug and alcohol abusers according to the primary drug of admission to treatment in Spain. <i>Drug and Alcohol Dependence</i> , 2014, 136, 115-120.	1.6	5
48	No Detectable Association Between Frequency of Marijuana Use and Health or Healthcare Utilization Among Primary Care Patients Who Screen Positive for Drug Use. <i>Journal of General Internal Medicine</i> , 2014, 29, 133-139.	1.3	22
49	Marijuana Use and Health in Primary Care. <i>Journal of General Internal Medicine</i> , 2014, 29, 282-282.	1.3	1
50	Impact of Medical Comorbidity and Risk of Death in 680 Patients with Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, E221-7.	1.4	30
51	Impact of Lifetime Alcohol Use on Liver Fibrosis in a Population of HIV-Infected Patients With and Without Hepatitis C Coinfection. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1527-1535.	1.4	20
52	Interleukin-6 Is Associated with Noninvasive Markers of Liver Fibrosis in HIV-Infected Patients with Alcohol Problems. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1110-1116.	0.5	19
53	Unhealthy Alcohol Use, HIV Infection and Risk of Liver Fibrosis in Drug Users with Hepatitis C. <i>PLoS ONE</i> , 2012, 7, e46810.	1.1	22
54	Estimated Liver Fibrosis and its Impact on All-Cause Mortality of HCV-Monoinfected and HCV/HIV-Coinfected Drug Users. <i>Current HIV Research</i> , 2011, 9, 256-262.	0.2	16

#	ARTICLE	IF	CITATIONS
55	Hepatitis B virus serum profiles in injection drug users and rates of immunization over time in Barcelona: 1987-2006. <i>Drug and Alcohol Dependence</i> , 2010, 110, 234-239.	1.6	10
56	Prevalence and routine assessment of unhealthy alcohol use in hospitalized patients. <i>European Journal of Internal Medicine</i> , 2010, 21, 458-464.	1.0	39
57	The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: A prospective cohort study. <i>Liver Transplantation</i> , 2009, 15, 1133-1141.	1.3	37
58	Paciente con abuso de alcohol, infecci3n por el VIH y hepatitis cr3nica C. <i>Trastornos Adictivos</i> , 2009, 11, 173-179.	0.1	0
59	Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients. <i>Open AIDS Journal</i> , 2008, 2, 82-88.	0.1	6
60	Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfecting patients. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 138-145.	0.6	46
61	Management of end-stage liver disease in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 474-481.	1.5	5
62	Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. <i>Journal of Viral Hepatitis</i> , 2007, 14, 070502203756001-???	1.0	8
63	Poor Response to Hepatitis C Virus (HCV) Therapy in HIV- and HCV-Coinfected Patients Is Not Due to Lower Adherence to Treatment. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 393-400.	0.5	26
64	Management of end stage liver disease (ESLD): What is the current role of orthotopic liver transplantation (OLT)?. <i>Journal of Hepatology</i> , 2006, 44, S140-S145.	1.8	50
65	Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. <i>Antiviral Therapy</i> , 2006, 11, 473-82.	0.6	7
66	Results of a Study of Prolonging Treatment with Pegylated Interferon-1±2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response. <i>Antiviral Therapy</i> , 2006, 11, 473-482.	0.6	21
67	Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 824-827.	1.3	7
68	Review of atazanavir: a novel HIV protease inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1565-1572.	0.9	23
69	Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. <i>Antiviral Therapy</i> , 2005, 10, 841-7.	0.6	4
70	Advanced Liver Fibrosis in HIV/HCV-Coinfected Patients on Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1293-1297.	0.5	44
71	Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection. <i>Aids</i> , 2004, 18, 59-66.	1.0	43
72	Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine, Stavudine or Both. <i>Antiviral Therapy</i> , 2004, 9, 969-977.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. <i>Journal of Viral Hepatitis</i> , 2003, 10, 118-125.	1.0	94
74	Chronic HCV Infection in HIV-Positive Patients: A New Challenge. <i>Journal of the International Association of Providers of AIDS Care</i> , 2003, 2, 56-58.	1.2	0
75	Spectrum of liver disease in patients with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection as compared to HCV infected patients. A case-control study. <i>Journal of Hepatology</i> , 2002, 36, 246.	1.8	0